Stocks
Iovance Biotherapeutics Financial Statements (IOVA) |
||||||||||
| Iovance Biotherapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2020 | 25.02.2021 | 24.02.2022 | 28.02.2023 | 28.02.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 0.000 | 0.000 | 1.19 | 1.90 | |||
| Operating Income, bln rub | -206.9 | -261.9 | -342.7 | -398.9 | -460.6 | -467.4 | ||||
| EBITDA, bln rub | ? | -206.9 | -260.8 | -342.7 | -398.9 | -427.4 | -447.8 | |||
| Net profit, bln rub | ? | -187.1 | -257.2 | -327.8 | -389.9 | -444.0 | -449.6 | |||
| OCF, bln rub | ? | -158.9 | -205.1 | -227.9 | -292.8 | -361.8 | -384.3 | |||
| CAPEX, bln rub | ? | 6.92 | 46.8 | 37.6 | 20.4 | 22.3 | 20.8 | |||
| FCF, bln rub | ? | -165.8 | -251.9 | -265.5 | -313.2 | -384.1 | -405.1 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 206.9 | 261.9 | 342.7 | 398.9 | 428.6 | 436.3 | ||||
| Cost of production, bln rub | 8.12 | 8.71 | 14.0 | 21.1 | 33.1 | 33.0 | ||||
| R&D, bln rub | 166.0 | 201.7 | 259.0 | 294.8 | 344.1 | 341.1 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 2.99 | 0.000 | 3.49 | ||||
| Assets, bln rub | 344.7 | 768.5 | 777.3 | 664.0 | 780.4 | 869.8 | ||||
| Net Assets, bln rub | ? | 299.0 | 656.5 | 621.7 | 499.6 | 584.6 | 680.0 | |||
| Debt, bln rub | 11.5 | 51.7 | 71.5 | 84.4 | 75.9 | 84.4 | ||||
| Cash, bln rub | 307.1 | 629.4 | 596.0 | 471.8 | 279.9 | 356.2 | ||||
| Net debt, bln rub | -295.6 | -577.8 | -524.5 | -387.4 | -204.0 | -271.8 | ||||
| Ordinary share price, rub | 27.7 | 46.4 | 19.1 | 6.39 | 8.13 | 3.88 | ||||
| Number of ordinary shares, mln | 124.3 | 138.3 | 153.4 | 159.3 | 235.1 | 266.2 | ||||
| Market cap, bln rub | 3 442 | 6 417 | 2 929 | 1 018 | 1 912 | 1 033 | ||||
| EV, bln rub | ? | 3 146 | 5 839 | 2 404 | 630 | 1 708 | 761 | |||
| Book value, bln rub | 299 | 656 | 622 | 500 | 355 | 386 | ||||
| EPS, rub | ? | -1.50 | -1.86 | -2.14 | -2.45 | -1.89 | -1.69 | |||
| FCF/share, rub | -1.33 | -1.82 | -1.73 | -1.97 | -1.63 | -1.52 | ||||
| BV/share, rub | 2.40 | 4.75 | 4.05 | 3.14 | 1.51 | 1.45 | ||||
| EBITDA margin, % | ? | -35 949% | -23 519% | |||||||
| Net margin, % | ? | -37 345% | -23 616% | |||||||
| FCF yield, % | ? | -4.82% | -3.93% | -9.07% | -30.8% | -20.1% | -39.2% | |||
| ROE, % | ? | -62.6% | -39.2% | -52.7% | -78.0% | -76.0% | -66.1% | |||
| ROA, % | ? | -54.3% | -33.5% | -42.2% | -58.7% | -56.9% | -51.7% | |||
| P/E | ? | -18.4 | -24.9 | -8.93 | -2.61 | -4.31 | -2.30 | |||
| P/FCF | -20.8 | -25.5 | -11.0 | -3.25 | -4.98 | -2.55 | ||||
| P/S | ? | 1 608 | 542.5 | |||||||
| P/BV | ? | 11.5 | 9.77 | 4.71 | 2.04 | 5.38 | 2.68 | |||
| EV/EBITDA | ? | -15.2 | -22.4 | -7.01 | -1.58 | -4.00 | -1.70 | |||
| Debt/EBITDA | 1.43 | 2.22 | 1.53 | 0.97 | 0.48 | 0.61 | ||||
| R&D/CAPEX, % | 2 400% | 431.1% | 689.4% | 1 443% | 1 544% | 1 640% | ||||
| CAPEX/Revenue, % | 1 875% | 1 092% | ||||||||
| Iovance Biotherapeutics shareholders | ||||||||||
